Inovio Pharmaceuticals, Inc.

PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conference:

World Federation of Hemophilia World Congress (Kuala Lumpur)

• Presentation: Next Gen Protein Replacement Therapeutics: DNA-Encoded Protein (DPROT) Technology Demonstrates in vivo Production of Functional FVIII in Mouse Model
  
  Date: Wednesday, April 22
  
  Time: 9:45 AM MYT

• Poster Presentation: FVIII Expression Via Non-viral Vector DNA Medicine Platform Results in Efficacious Levels of FVIII Protein and Correction of the Bleeding Phenotype in Hemophilia A Mice
  
  Date: Wednesday, April 22
  
  Time: 10:45 AM MYT

Available abstracts will be shared on INOVIO's website following presentations.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts

Media: Jennie Willson, (267) 429-8567, communications@inovio.com

Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conference-302731455.html

SOURCE INOVIO Pharmaceuticals, Inc.

NEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Inovio Pharmaceuticals, Inc. ("Inovio Pharmaceuticals, Inc." or the "Company") (NASDAQ: INO) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inovio Pharmaceuticals, Inc. investors who were adversely affected by alleged securities fraud between October 10, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/inovio-pharmaceuticals-inc-lawsuit-submission-form?prid=185115&wire=4

INO investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated; and (v) as a result, defendants' public statements were materially false and misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in Inovio Pharmaceuticals, Inc. during the relevant time frame, you have until April 7, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-pharmaceuticals-inc-securities-fraud-class-action-lawsuit-pending-contact-levi--korsinsky-before-april-7-2026-to-discuss-your-rights--ino-302731001.html

SOURCE Levi & Korsinsky, LLP